（来源：邯郸日报） 转自：邯郸日报 本报讯（王芳 张君）常年鼻塞流涕、反复喷嚏不断，夜间呼吸不畅影响睡眠，白天精神萎靡难以专 注……鼻炎这一常见健康问题，正持续困扰着众多市民的日常生活。为破解鼻炎诊疗难题，提供精准 化、系统化解决方案，邯郸市第一医院睡眠医学科鼻炎专病门诊正式运营，凭借前沿诊疗理念、专业医 疗技术和个性化治疗方案，助力广大鼻炎患者摆脱疾病困扰，重拾顺畅呼吸与优质睡眠。 据悉，鼻炎种类繁杂，涵盖过敏性、非过敏性、混合性等多种类型，其发病机制涉及免疫失衡、神经调 节紊乱、局部解剖变异等多个方面，且与睡眠呼吸障碍等全身健康问题密切相关。传统泛化诊疗模式往 往难以直击病灶，易导致病情反复难愈。基于此，邯郸市第一医院设立鼻炎专病门诊，以"深度精准"为 核心诊疗原则，打造专病专治的特色医疗服务。 该门诊的诊疗特色鲜明突出，实现了"检查—诊断—治疗—随访"的全流程闭环管理。门诊通过详细问 诊、精准鼻内镜检查及必要的过敏原检测，为患者明确鼻炎具体类型与核心发病机制，从根源上避 免"一刀切"的治疗误区；同时推行"评估—精准干预—长期管理"的全程诊疗模式，不仅为患者提供对症 治疗方案，还量身定制长期健康管理计划， ...

Company Performance - Medpace (MEDP) closed at $616.45, marking a +1.32% move from the prior day, outperforming the S&P 500's daily loss of 0.53% [1] - The stock has risen by 8.89% in the past month, leading the Medical sector's gain of 0.09% and the S&P 500's gain of 2.06% [1] Upcoming Earnings - Medpace's earnings report is set to be unveiled on February 9, 2026, with projected earnings per share (EPS) of $4.18, reflecting a 13.9% increase from the same quarter last year [2] - The Zacks Consensus Estimate for revenue is projecting net sales of $681.17 million, up 26.94% from the year-ago period [2] Full Year Estimates - Analysts expect earnings of $14.8 per share and revenue of $2.5 billion for the full year, marking changes of +17.18% and 0%, respectively, from last year [3] Analyst Forecasts - Recent revisions to analyst forecasts for Medpace are important as they indicate changing near-term business trends, with positive alterations signifying analyst optimism regarding the business and profitability [4] Valuation Metrics - Medpace is currently traded at a Forward P/E ratio of 36.6, which is a premium compared to its industry average Forward P/E of 15.3 [7] - The company has a PEG ratio of 2.04, compared to the Medical Services industry's average PEG ratio of 1.91 [7] Industry Ranking - The Medical Services industry holds a Zacks Industry Rank of 194, positioning it in the bottom 21% of all 250+ industries, indicating weaker performance compared to higher-ranked industries [8]

Group 1 - The A-share market showed mixed performance with the Shanghai Composite Index down by 0.31%, while the Shenzhen Component Index and the ChiNext Index rose by 0.56% and 0.82% respectively [1] - The total trading volume reached a record high of 3.99 trillion yuan, surpassing the previous day's 3.66 trillion yuan, indicating strong market participation and enthusiasm [1] - The increase in trading volume is attributed to significant inflows of capital from domestic and foreign investment institutions and individual investors [1] Group 2 - In the Hunan stock market, less than half of the stocks saw price increases, with notable gainers including Changlan Technology and Heshun Petroleum, both rising over 10% [2] - The commercial aerospace sector remained sluggish, with stocks like Shaoyang Hydraulic and Hualing Cable experiencing declines of 9.64% and 5.58% respectively [2] - Other sectors such as medical services, biopharmaceuticals, and chemical pharmaceuticals also showed low activity, with companies like Erkang Pharmaceutical and Huana Pharmaceutical both down by 3.19% [2]

打造家门口"健康驿站" 1月8日，工作人员上门为社区居民诊疗。 崇信县医疗卫生服务机构在社区设立专属医疗服务点，常态化开展形式多样健康知识宣传、健康知识咨询和免费医疗服 务，为居民群众提供全方位、便捷化、高品质一站式基本公共卫生服务，将专业医疗服务送到居民家门口，守护好居民 群众的身体健康与生命安全。 平凉日报记者 梁明韬 摄 责任编辑：樊醒民 ...

Core Viewpoint - The healthcare system in Jiangsu has significantly improved during the "14th Five-Year Plan" period, enhancing accessibility and quality of medical services for residents, particularly in community healthcare settings [1][17]. Group 1: Healthcare Accessibility - Jiangsu has focused on strengthening county-level hospitals, with 84.5% of county hospitals upgraded to tertiary hospitals, and 95% of patients now receiving care within their counties [2][3]. - The establishment of 256 internet hospitals aims to provide convenient online medical services, with a target of serving over 50 million people by 2025 [6]. - The implementation of a policy allowing patients to revisit the same department within three days without re-registering has streamlined the healthcare process [6]. Group 2: Quality of Medical Services - Investment of 4.1 billion yuan has been directed towards developing 16 high-level hospitals, enhancing specialized medical capabilities in areas such as lung transplants and critical care [3]. - The introduction of advanced medical technologies, such as the world's first Y-90 microsphere treatment for liver cancer, showcases the integration of cutting-edge procedures into local healthcare [2]. Group 3: Community Health Management - Jiangsu has shifted from single diagnosis to comprehensive health management, exemplified by personalized health services provided by family doctors [3]. - The establishment of 120 chronic disease screening and prevention centers has improved early detection and management of conditions like hypertension and diabetes [4]. Group 4: Elderly and Child Healthcare - The province has implemented priority services for elderly patients, including zero-waiting times for those over 80 years old, enhancing their healthcare experience [5][8]. - The development of a robust pediatric healthcare network allows children to receive timely treatment for common illnesses at local facilities [11]. Group 5: Traditional Chinese Medicine (TCM) - Jiangsu has achieved full coverage of community TCM clinics, with 352 clinics established, reflecting a significant increase in TCM services [14]. - The integration of TCM into the healthcare system has been supported by training programs for local practitioners, ensuring high-quality care is accessible [15][16].

Summary of Sotera Health Company FY Conference Call Company Overview - **Company Name**: Sotera Health Company (NasdaqGS:SHC) - **Mission**: Safeguarding global health through its three business units: Sterigenics, Nordion, and Nelson Labs [2][3] - **Global Presence**: Over 5,000 customers in 50 countries, 3,100 employees, and 62 facilities across 13 countries [3] - **Customer Base**: Engages with 40 of the top 50 medical device companies and 9 of the top 10 pharmaceutical companies [3] Business Segments Sterigenics - **Largest Business Unit**: Represents about two-thirds of the company's revenue [4] - **EBITDA Margins**: Approximately 50% [4] - **Sterilization Methods**: 39% ethylene oxide, 49% gamma, and 12% eBeam [5] - **Service Model**: Operates as a service business, where customers drop off products for sterilization [5] Nordion - **Product Business**: World's largest provider of Cobalt-60, critical for sterilization [6] - **EBITDA Margins**: Approximately 60% [7] - **Cobalt Sourcing**: Obtains Cobalt-60 from reactors in multiple countries including China, Canada, and Russia [6] Nelson Labs - **Testing Services**: Leader in microbiological and analytical chemistry testing with about 3,000 customers [7] - **Revenue Composition**: 48% routine testing, 37% validation, and 15% advisory services [8] Financial Performance - **Revenue Growth**: Surpassed $1.16 billion in revenue, with a minimum growth of over 5% [10] - **CAGR**: 7% growth in top line and adjusted EBITDA since going public in 2020 [11] - **Free Cash Flow**: Targeting $500 million to $600 million in cumulative free cash flow from 2025 to 2027 [20] - **Leverage Ratio**: Aiming to reduce net leverage from 3.3 times to a target of 2-3 times [12] Strategic Priorities 1. **Customer Service Excellence**: Focus on providing end-to-end solutions [13] 2. **Growth Market Segmentation**: Targeting high-growth segments within med tech and pharma [14] 3. **Operational Excellence**: Enhancing free cash flow through disciplined capital deployment [15] 4. **Long-term Value Creation**: Aiming for consistent top-line growth of 5%-7% annually [17] Market Outlook - **Growth Projections**: Sterigenics expected to grow mid-single to high-single digits, Nelson Labs mid-single digits, and Nordion low-single to mid-single digits [18] - **Pricing Strategy**: Anticipating a price increase of 3%-4% across the company [30] Regulatory Environment - **NESHAP Standards**: New regulations for ethylene oxide have been extended to April 2028, impacting smaller competitors [33] - **Litigation Updates**: Favorable rulings in Georgia regarding ethylene oxide litigation, with ongoing cases in California [52][54] Investment Rationale - **Market Position**: Leader in a growing $18 billion addressable market with strong margins and cash flow [24] - **Regulatory Expertise**: Established expertise in navigating highly regulated markets [24] - **Growth Potential**: Continued investment in capacity and operational improvements expected to drive future growth [25] Conclusion - **Company Confidence**: Strong execution and commitment to delivering growth and cash flow, positioning Sotera Health as a compelling investment opportunity for the future [55]

"医疗卫生机构应立足主责主业，不得开展殡仪服务。"根据最新规定，医疗机构被叫停殡仪服务。 近期，国家卫生健康委会同公安部、民政部、市场监管总局、国家中医药局、国家疾控局五部门联合制 定了《医疗卫生机构亡故患者全流程服务管理规定》（以下简称《规定》），该文件于今日（1月12 日）对外公布，其中对死亡证明签发主体、签发流程、遗体存放与转运等内容进行了明确。 国家卫健委介绍，殡葬是关系千家万户的民生问题，关乎群众的切身利益。2024年10月，全国整治殡葬 领域腐败乱象专项行动启动，各地区和有关部门按照职责推进殡葬改革，国家卫生健康委联合国家中医 药局、国家疾控局组织开展了卫生健康系统整治殡葬领域腐败乱象专项行动。 为进一步巩固专项行动成果，形成制度化、长效化政策措施，规范医疗卫生机构亡故患者全流程服务， 国家卫生健康委总结专项行动经验，针对医疗卫生机构亡故患者服务管理工作中存在的困难问题，广泛 听取医疗卫生机构和群众的意见建议，会同公安部、民政部、市场监管总局、国家中医药局、国家疾控 局等部门，联合制定了本《规定》。 焦点1 其中还提到，医疗卫生机构严禁接收和存放院外来源的遗体，不得承担其他部门委托的遗体存放业务。 ...

Market Overview - The A-share market saw all three major indices rise collectively, with the Shanghai Composite Index surpassing 4150 points, closing at 4151.14 points, up 0.75% [1] - The total trading volume in the Shanghai and Shenzhen markets reached 2.31 trillion yuan, an increase of 245.5 billion yuan compared to the previous trading day [2] Sector Performance - The cultural media, software development, and commercial aerospace sectors led the gains, while the insurance and oil & gas sectors experienced declines [2] - The Sora concept stocks surged, with multiple stocks hitting their daily limit [2] Sora Concept Stocks - Notable Sora concept stocks included: - Liu Jin Technology: +29.92% - Tuoer Si: +20.02% - Yi Dian Tian Xia: +20.00% - Zhong Wen Online: +20.00% [3][4] - The AI application sector saw a resurgence, with Sora concept stocks experiencing significant price increases [2] Commercial Aerospace Sector - The commercial aerospace sector continued to strengthen, with satellite communication and satellite industry indices rising over 9% [5] - Key stocks in this sector included: - China Satellite: 10% limit up - Star Map Measurement and Control: 30% limit up - Tianyin Machinery: 20% limit up [6][7] Medical Services Sector - The medical services sector also saw gains, with stocks like Di'an Diagnosis and Meinian Health recording consecutive limit ups [9] - The upcoming JPMorgan Global Healthcare Conference is expected to highlight key areas in biotechnology, biopharmaceuticals, and medical services [10]

Company Performance - Progyny (PGNY) has seen a stock increase of 5.5% over the past month, reaching a new 52-week high of $28.49 [1] - Year-to-date, Progyny's stock has gained 6.8%, compared to 7.8% for the Zacks Medical sector and 10.9% for the Zacks Medical Services industry [1] Earnings and Revenue - Progyny has consistently beaten earnings estimates, with a reported EPS of $0.45 against a consensus estimate of $0.39 in its last earnings report [2] - For the current fiscal year, Progyny is expected to post earnings of $1.93 per share on revenues of $1.27 billion, with a year-over-year change of 7.22% [3] - For the next fiscal year, earnings are projected to be $2.11 per share on revenues of $1.39 billion, reflecting a year-over-year change of 9.24% [3] Valuation Metrics - Progyny's current valuation metrics show a trading multiple of 14.2X current fiscal year EPS estimates, below the peer industry average of 15.3X [7] - The stock trades at a trailing cash flow basis of 79.5X compared to the peer group's average of 11.2X, and has a PEG ratio of 0.85 [7] Zacks Rank and Style Scores - Progyny holds a Zacks Rank of 2 (Buy) due to a solid earnings estimate revision trend [8] - The company has a Value Score of B, a Growth Score of A, and a Momentum Score of C, resulting in a combined VGM Score of A [6][8] Industry Comparison - In comparison to peers, Enhabit, Inc. (EHAB) also shows strong performance with a Zacks Rank of 2 (Buy) and a Value Score of A [9] - Enhabit, Inc. reported earnings that beat consensus estimates by 41.67%, with expected earnings of $0.53 per share on revenue of $1.06 billion for the current fiscal year [10]

Industry Overview - The Medical Services sector is rapidly evolving due to digital health advancements, value-based care adoption, and a focus on patient-centric solutions [1] - The global healthcare analytics market is projected to grow from $56.64 billion in 2025 at a CAGR of 22.7% through 2035, benefiting payers, providers, and analytics vendors [1] - The industry includes various service providers such as pharmacy benefit managers, contract research organizations, and healthcare workforce solution providers, transitioning from volume-based to value-based care [3] Key Trends - The U.S. digital health market is expected to grow from $92.08 billion in 2025 to $248.11 billion by 2034, with a CAGR of 11.6% [4] - The global big data in healthcare market is valued at $110.97 billion in 2025, projected to grow at a CAGR of 19.2% from 2026 to 2035 [4] - Companies adopting AI technologies have seen a 50% reduction in treatment costs and over 50% improvement in patient outcomes [4] Workforce Challenges - A projected healthcare worker shortage of 100,000 by 2028, including a shortfall of 73,000 nursing assistants, is expected to elevate labor costs [2][5] - The WHO estimates a shortfall of 11 million physicians, particularly in low-income countries, emphasizing the need for workforce expansion [5] - Total hospital expenses increased by 5.1% in 2024, significantly outpacing the overall inflation rate of 2.9% [5] Company Highlights - **Medpace Holdings (MEDP)**: Expected earnings growth rate of 17.2% in 2025, with revenues projected to rise by 18.7% from 2024 [19][20] - **Enhabit, Inc. (EHAB)**: Anticipated earnings surge of 161.9% in 2025, with revenue growth of 2.3% [23][24] - **Progyny (PGNY)**: Projected earnings increase of 9.8% in 2025, with revenues expected to grow by 9.2% [26][27] Performance Metrics - The Medical Services industry has gained 6.8% over the past year, in line with the Medical sector, but lagged behind the S&P 500's 19.3% increase [10] - The industry is currently trading at a forward P/E of 16.9X, compared to the S&P 500's 23.3X and the sector's 21.6X [14]